ACRS vs AZN

ACRS exhibits severe financial distress despite a strong analyst consensus, as evidenced by a Piotroski F-Score of 1/9 indicating extreme weakness in operational and financial health. The company reports negative profitability across all key margins, with a staggering -1724.63% operating margin and a -50.20% ROE, signaling deep operational inefficiency. Although the debt-to-equity ratio is low (0.02) and liquidity is strong (current ratio 3.36), the company's revenue has collapsed by 85.9% YoY, and it continues to burn cash with no free cash flow. The absence of a Graham Number and intrinsic value estimate underscores the lack of a reliable valuation anchor, while the stock trades at an inflated Price/Sales of 54.77, suggesting extreme speculative pricing. Despite a recent 126.9% 1-year return, the underlying fundamentals remain critically deteriorating.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.